A First-in-human, Dose Escalation and Dose Expansion Study of SAR445877 in Adult Participants With Advanced Solid Tumors

NCT05584670 · clinicaltrials.gov ↗

PHASE1,PHASE2

Phase

RECRUITING

Status

542

Enrollment

INDUSTRY

Sponsor class

Conditions

Solid Tumor

Interventions

DRUG: SAR445877
DRUG: Cetuximab
DRUG: ADG126
DRUG: Bevacizumab
DRUG: Nivolumab
DRUG: Ipilimumab

Sponsor

Sanofi